文献速递神经介入MRDSA

取栓后FLAIR高信号血管细化mTICI再灌注分型

Posttreatment FLAIR Hyperintense Vessels Refine mTICI-Based Reperfusion Phenotypes After Endovascular Thrombectomy.
PubMed 文献 · AJNR Am J Neuroradiol · 2026-08-11

该回顾性队列研究纳入205例因ICA/M1/M2闭塞接受血管内取栓且具备最终mTICI分级、术后FLAIR及90天mRS的患者,按mTICI与FHV状态分为四型。在mTICI 2b-3再灌注患者中,FHV+组90天良好功能结局率低于FHV-组,持续FHV与良好结局独立相关。

要点

  • 术后FLAIR高信号血管(NIH-FHV>0)提示再灌注后仍存在血流障碍,即使mTICI 2b-3也不宜简单报为完全成功。
  • mTICI 2b-3且FHV+患者90天良好预后率低于FHV-者,报告时可提示临床关注该不一致表型。
  • NIH-FHV每增加1分与良好结局概率降低相关,阅片应逐分记录而非仅报有或无。

核心结论

  • 术后FLAIR高信号血管可细化ICA/M1/M2取栓后基于mTICI的再灌注分型。
  • 在mTICI 2b-3再灌注患者中,持续FHV识别出一种临床不一致表型,与较低90天良好功能结局率相关。

研究设计与样本

  • 回顾性队列研究,纳入205例因ICA、M1或M2闭塞接受EVT且具备最终mTICI分级、术后FLAIR及有效90天mRS的急性缺血性卒中患者。

关键影像表现/征象

  • 术后FLAIR序列上高信号血管(FHV)按NIH-FHV评分二分为FHV-(评分0)与FHV+(评分>0),提示再灌注后残留血流异常。

诊断标准与关键数值

  • 成功血管造影再灌注定义为mTICI 2b-3。
  • 90天良好功能结局定义为mRS 0-2。
  • mTICI 2b-3再灌注患者中,FHV-组84/132例(63.6%)达良好结局,FHV+组21/49例(42.9%)。
  • 持续FHV与较低良好结局调整后概率相关(调整后OR,0.26;95%CI,0.11-0.57;p<.001)。
  • NIH-FHV评分每增加1分同样与较低良好结局概率相关(调整后OR,0.62;95%CI,0.45-0.83;p=.002)。

临床应用与阅片要点

  • 取栓术后需关注FLAIR上FHV,mTICI 2b-3但FHV+者应提示临床预后可能较差。
  • 报告FHV应用NIH-FHV评分逐分记录,分值越高提示良好功能结局概率越低。

局限性

  • 回顾性设计存在选择与信息偏倚风险。
  • 仅纳入具备完整术后FLAIR与90天mRS的患者,可能存在样本代表性偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: The modified Thrombolysis in Cerebral Infarction (mTICI) scale is the standard angiographic measure of reperfusion after endovascular thrombectomy (EVT), but outcomes remain heterogeneous even after successful mTICI 2b-3 reperfusion. We evaluated whether posttreatment FLAIR hyperintense vessels (FHV) refine mTICI-based reperfusion phenotypes and identify patients with worse 90-day functional outcome after EVT for ICA, M1, or M2 occlusions.

MATERIALS AND METHODS: This retrospective cohort study included patients with acute ischemic stroke due to ICA, M1, or M2 occlusion treated with EVT who had available final mTICI grade, posttreatment FLAIR assessment, and valid 90-day modified Rankin Scale (mRS). Successful angiographic reperfusion was defined as mTICI 2b-3. FHV status was dichotomized as FHV-, defined as NIH-FHV score 0, versus FHV+, defined as NIH-FHV score >0. Patients were categorized into four mTICI/FHV phenotypes. The primary outcome was favorable 90-day functional outcome, defined as mRS 0-2. Multivariable logistic regression was performed among patients with mTICI 2b-3 reperfusion, with FHV analyzed both dichotomously and per 1-point increase in NIH-FHV score.

RESULTS: A total of 205 patients were included: 132 had mTICI 2b-3/FHV-, 49 had mTICI 2b-3/FHV+, 8 had mTICI <2b/FHV-, and 16 had mTICI <2b/FHV+. Favorable 90-day outcome differed across phenotypes (p=.001). Among patients with mTICI 2b-3 reperfusion, favorable outcome occurred in 84/132 patients with FHV- (63.6%) versus 21/49 with FHV+ (42.9%). Persistent FHV was associated with lower adjusted odds of favorable outcome (adjusted OR, 0.26; 95% CI, 0.11-0.57; p<.001), and each 1-point increase in NIH-FHV score was similarly associated with lower odds (adjusted OR, 0.62; 95% CI, 0.45-0.83; p=.002).

CONCLUSIONS: Posttreatment FHV refined mTICI-based reperfusion phenotyping after ICA/M1/M2 EVT. Among patients with mTICI 2b-3 reperfusion, persistent FHV identified a clinically discordant phenotype associated with lower rates of favorable 90-day functional outcome.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Tsang, Gad, Lalwani, et al. Posttreatment FLAIR Hyperintense Vessels Refine mTICI-Based Reperfusion Phenotypes After Endovascular Thrombectomy. AJNR Am J Neuroradiol. 2026. PMID: 42580861. doi:10.3174/ajnr.A9584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。